Ethnic and genetic determinants of omeprazole disposition and effect

Clinical Pharmacology and Therapeutics

Volumn 60, Issue 2, 1996, Pages 157-167

  Caraco, Yoseph ^a,b   Lagerstrom, Per Olaf ^a   Wood, Alastair J J ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

DEBRISEQUINE; DEBRISOQUINE; DRUG METABOLITE; GASTRIN; MEPHENYTOIN; OMEPRAZOLE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CAUCASIAN; CHINESE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG METABOLISM; ENZYME ACTIVITY; ETHNIC DIFFERENCE; HEREDITY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADULT; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; EUROPEAN CONTINENTAL ANCESTRY GROUP; GASTRINS; HUMANS; MALE; MEPHENYTOIN; OMEPRAZOLE;

EID: 0029955476     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(96)90131-9     Document Type: Article

References (40)

1. Wood AJJ, Zhou HH. Ethnic differences in drug disposition and responsiveness. Clin Pharmacokinet 1991;20:350-73.
2. Kalow W. Interethnic variation of drug metabolism. Trends Pharmacol Sci 1991;12:102-7.
3. Wang SL, Huang JD, Lai MD, Liu BH, Lai ML. Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: polymorphism in RFLP and DNA sequence of CYP2D6. Clin Pharmacol Ther 1993;53:410-8.
4. Mura C, Broyard JP, Jacoq-Aigrain E, Krishnamoorthy R. Distinct phenotypes and genotypes of debrisoquin hydroxylation among Europeans and Chinese. Br J Clin Pharmacol 1991;32:135-6.
5. Bertilsson L, Lou YQ, Du YL, Liu Y, Kuang TY, Liao XM, et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 1992;51:388-97.
6. Wedlund PJ, Aslanian WS, McAllister CB, Wilkinson GR, Branch RA. Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther 1984;36:773-80.
7. Alvan G, Bechtel P, Iselius L, Gundert-Remy U. Hydroxylation polymorphisms of debrisoquin and mephenytoin in European populations. Eur J Clin Pharmacol 1990;39:533-7.
8. Woodhouse NM, Eichelbaum M, Dates NS, Idle JR, Smith RL. Dissociation of co-regulatory control of debrisoquin/phenformin and sparteine oxidation in Ghanaians. Clin Pharmacol Ther 1985;37:512-21.
9. Zhang Y, Reviriego J, Lou YQ, Sjöqvist F, Bertilsson L. Diazepam metabolism in native Chinese poor and extensive hydroxylators of S-mephenytoin: interethnic differences in comparison with white subjects. Clin Pharmacol Ther 1990;48:496-502.
10. Caraco Y, Tateishi T, Wood AJJ. Interethnic difference in omeprazole's inhibition of diazepam metabolism. Clin Pharmacol Ther 1995;58:62-74.
11. Caraco Y, Wilkinson GR, Wood AJJ. In vivo screening for P450 mediated drug interactions with omeprazole [abstract]. Clin Pharmacol Ther 1994;55:209.
12. Maton PN. Drug therapy - omeprazole. N Engl J Med 1991;324:965-75.
13. Regårdh CG, Andersson T, Lagerstrom PO, Lundborg P, Skanberg I. The pharmacokinetics of omeprazole in humans - a study of single intravenous and oral doses. Ther Drug Monit 1990;12:163-72.
14. Andersson T, Regårdh CG, Lou YC, Zhang Y, Dahl ML, Bertilsson L. Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics 1992; 2:25-31.
15. Andersson T, Miners JO, Veronese M, Tassaneeyakul W, Tassaneeyakul W, Meyer UA, et al. Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol 1993; 36:521-30.
16. Sohn DR, Kobayashi K, Chiba K, Lee KH, Shin SG, Ishizaki T. Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4′-hydroxylation recruited from an oriental population. J Pharmacol Exp Ther 1992;262: 1195-202.
17. Chiba K, Kobayashi K, Manabe K, Tani M, Kamotaki T, Ishizaki T. Oxidative metabolism of omeprazole in human liver microsomes: co-segregation with S-mephenytoin 4-hydroxylation. J Pharmacol Exp Ther 1993;226:52-9.
18. Balian JD, Sukhova N, Harris JW, Hewet J, Pickle L, Goldstein JA, et al. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study. Clin Pharmacol Ther 1995;57:662-9.
19. Curi-Pedrosa R, Pichard L, Bonfils C, Jacoz-Aigrain E, Maurel P. Major implication of cytochrome P4503A4 in the oxidative metabolism of the anti-secretory drugs omeprazole and lansoprazole in human liver microsomes and hepatocytes. Br J Clin Pharmacol 1993;36:156p.
20. Andersson T, Miners JO, Veronese ME, Birkett DJ. Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism. Br J Clin Pharmacol 1994;37:597-604.
21. Andersson T, Regårdh CG, Dahl-Puustinen ML, Bertilsson L. Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther Drug Monit 1990; 12:415-6.
22. Cederberg C, Andersson T, Skanberg I. Omeprazole: pharmacokinetics and metabolism in man. Scand J Gastroenterol 1989;24(suppl 166):33-40.
23. Olbe L, Cederberg C, Lind T, Olausson M. Effect of omeprazole on gastric acid secretion and plasma gastrin in man. Scand J Gastroenterol 1989;24(suppl 166):27-32.
24. Lind T, Cederberg C, Ekenved G, Haglund U, Olbe L. Effect of omeprazole - a gastric proton pump inhibitor - on pentagastrin stimulated acid secretion in man. Gut 1983;24:270-6.
25. Lind T, Cederberg C, Forssell H, Olausson M, Olbe L. Relationship between reduction of gastric acid secretion and plasma gastrin concentration during omeprazole treatment. Scand J Gastroenterol 1988;23:1259-66.
26. Yasuda S, Horai Y, Tomono Y, Nakai H, Chiba K, Ishizaki T. Pharmacokinetics of E3810 and omeprazole in relation to polymorphic hydroxylation of S-mephenytoin [abstract]. Clin Pharmacol Ther 1994; 55:165.
27. Rehfeld JF, Stadil F, Rubin B. Production and evaluation of antibodies for the radioimmunoassay of gastrin. Scand J Clin Lab Invest 1972;30:221-32.
28. Lagerstrom PO, Persson BA. Determination of omeprazole and metabolites in plasma and urine by liquid chromatography. J Chromatogr 1984;309:347-56.
29. Caraco Y, Wilkinson G, Wood AJJ. Difference between white subjects and Chinese subjects in the in vivo inhibition of cytochromes P450s 2C19, 2D6, and 3A by omeprazole. Clin Pharmacol Ther [in press].
30. Wedlund PJ, Sweetman BJ, McAllister RA, Branch RA, Wilkinson GR. Direct enantiomeric resolution of mephenytoin and its N-demethylated metabolite in plasma and blood using chiral capillary gas chromatography. J Chromatogr 1984;307:121-7.
31. Bertilsson L, Kalow W. Why are diazepam metabolism and polymorphic S-mephenytoin associated with each other in white and Korean populations but not in Chinese populations? Clin Pharmacol Ther 1993:56: 608-10.
32. Ishizaki T, Sohn DR, Kobayashi K, Chiba K, Lee KH, Shin SG, et al. Interethnic differences in omeprazole metabolism in two S-mephenytoin hydroxylation phenotypes studies in Caucasians and Orientals. Ther Drug Monit 1994;16:214-5.
33. Howden CW. Appropriate acid suppression in the treatment of acid-related conditions. Pharmacol Ther 1994;63:123-34.
34. Hunt RH, Cederberg C, Dent J, Halter F, Howden CW, Marks INS, et al. Optimizing acid suppression for the treatment of acid-related diseases. Dig Dis Sci 1995;40(suppl):24S-49S.
35. Savarino V, Mela GS, Zentilin P, Cutela P, Mele MR, Vigneri S, et al. Variability in individual response to various doses of omeprazole; implications for antiulcer therapy. Dig Dis Sci 1994;39:161-8.
36. Chang K, Tybring G, Dahl ML, Gotharson E, Sagar M, Seensalu R, et al. Interphenotype differences and the effect on gastrin levels of omeprazole - suitability of omeprazole as a probe for CYP2C19. Br J Clin Pharmacol 1995;39:511-8.
37. Andersson T, Cederberg C, Heggelund A, Lundborg P. The pharmacokinetics of single and repeated once-daily doses of 10, 20 and 40 mg omeprazole as enteric coated granules. Drug Invest 1991;3:45-52.
38. Andersson T, Bergstrand R, Cederberg C. Influence of acid secretory status on absorption of omeprazole from enteric coated granules. Br J Clin Pharmacol 1991;31:275-8.
39. Andersson T. Pharmacokinetics of omeprazole in man: with special reference to single and repeated administration, drug interactions, and polymorphic metabolism [PhD Thesis]. Goteborg, Sweden: University of Goteborg; 1991:1-41.
40. 13C-[N-3-methyl-]-caffeine breath test in poor and extensive metabolizers of 5-mephenytoin. Clin Pharmacol Ther 1992;52:170-80.